

# Contents

<b>1</b>	<b>Introduction</b>	<b>1</b>
1.1	Background	1
1.2	Polymorphism	3
1.3	Multi-component Crystalline Systems: Solvates, Salts and Co-crystals	4
1.4	Amorphous Solids	6
1.5	Importance of Solid-State Form for Pharmaceutical Industry	6
1.6	Crystallisation	7
1.7	Crystallisation Techniques	8
1.8	Control of Solid Form	10
1.9	Computational Methods	13
1.9.1	Crystal Structure Prediction	13
1.9.2	Energetics of Non-bonded Interactions: The PIXEL/Semi-classical Density Sums Methods	16
1.10	Experimental and Computational Studies on Structurally Related Compounds	18
	References	23
<b>2</b>	<b>Aims and Objectives</b>	<b>29</b>
2.1	Aims	29
2.2	Objectives	30
<b>3</b>	<b>Materials and Methods</b>	<b>31</b>
3.1	Material	31
3.2	Methods	31
3.2.1	Crystallisation Techniques	31
3.2.2	X-Ray Crystallography	33
3.2.3	Thermal Analysis	35
3.2.4	Raman and Infrared Spectroscopy	35
3.2.5	PIXEL Calculations	35
3.2.6	Crystal Packing Analysis	36
	References	36

<b>4</b>	<b>Development and Validation of High-Throughput Crystallisation and Analysis (HTCAA) Methodology for Physical Form Screening.</b>	<b>39</b>
4.1	Introduction.	39
4.2	Sample Preparation and Methodology Development	45
4.2.1	96/48 Quartz Multi-well Plate	45
4.2.2	Preparation of 96-Well Plate for Salt Screening of Amoxapine	46
4.2.3	Preparation of 48-Well Plate for Physical Form Screening of Clozapine.	47
4.2.4	Preparation of 96-Well Plate for Physical Form Screening of Olanzapine	47
4.2.5	Raman Microscopy	49
4.2.6	Chemometric Analysis	50
4.2.7	Scale-up and Characterisation of Novel Forms.	51
4.3	Results and Discussion	52
4.3.1	Salt Screening of Amoxapine	52
4.3.2	Physical Form Screening of Clozapine	60
4.3.3	Physical Form Screening of Olanzapine	65
4.4	Key Findings of the Developed HTCAA Methodology	70
4.5	Summary	73
	References	74
<b>5</b>	<b>Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques</b>	<b>77</b>
5.1	Statistical Modelling Techniques	77
5.1.1	Introduction.	77
5.1.2	Principal Component Analysis.	78
5.1.3	Criteria for Deciding the Number of Principal Components	79
5.1.4	Random Forests Classification Method	80
5.1.5	Applications of Statistical Modelling Techniques in Pharmaceutical Industry	82
5.2	Descriptor Calculations, Model Building and Validation	86
5.2.1	Training Dataset and 2- and 3-Dimensional Descriptors Calculations	86
5.2.2	Training the Statistical Model	88
5.3	Results and Discussion	88
5.3.1	Principal Component Analysis	88
5.3.2	Random Forests Classification Model	89
5.3.3	Model Optimisation Attempts	91
5.3.4	Important Descriptors Assessment	93
5.3.5	Limitations of Random Forests Classification Model.	94
5.4	Summary	95
	References	95

<b>6</b>	<b>Exploring the Crystal Structure Landscape of Olanzapine . . . . .</b>	<b>99</b>
6.1	Introduction. . . . .	99
6.2	Experimental Procedures. . . . .	102
6.2.1	Crystallisation . . . . .	102
6.2.2	Variable Temperature-X-Ray Powder Diffraction . . . . .	105
6.2.3	XPac Analysis of Crystal Structures of Olanzapine. . . . .	105
6.2.4	Random Forests Classification Model of Olanzapine Solvates . . . . .	106
6.3	Calculation and Analysis of the Crystal Energy Landscape (Crystal Structure Prediction) of Olanzapine . . . . .	106
6.4	Results and Discussion . . . . .	109
6.4.1	Forms I, II and III of Olanzapine . . . . .	109
6.4.2	Solution Crystallisation of Olanzapine . . . . .	112
6.4.3	Neat and Liquid-Assisted Grinding of Olanzapine . . . . .	118
6.4.4	Desolvation of Olanzapine Solvates . . . . .	120
6.4.5	Melt Quenching and Recrystallisation of Amorphous Olanzapine . . . . .	120
6.4.6	Spray Drying and Freeze Drying of Olanzapine . . . . .	123
6.5	Molecular Packing Analysis of Olanzapine Crystal Structures Using XPac. . . . .	123
6.6	Hydrogen-Bonding Analysis of Olanzapine Crystal Structures . . . . .	127
6.6.1	Hydrogen Bonding in Olanzapine Solvates Based on Packing Type SC <sub>31</sub> . . . . .	129
6.6.2	Hydrogen Bonding in Olanzapine Solvates Based on Packing Type SC <sub>32</sub> . . . . .	129
6.6.3	Hydrogen Bonding in Olanzapine Solvates Based on Packing Type, SC <sub>33</sub> . . . . .	130
6.6.4	Hydrogen Bonding in Other Olanzapine Solvates Based on SC <sub>0</sub> , SC <sub>11</sub> and SC <sub>22</sub> . . . . .	131
6.7	Prediction of Olanzapine Solvate Formation Using Random Forests Classification Model . . . . .	132
6.7.1	Random Forests Classification Model – Prediction Results . . . . .	132
6.7.2	Important Solvent Physicochemical Descriptors for Random Forests Classification Model of Olanzapine Solvates . . . . .	136
6.8	Crystal Energy Landscape of Olanzapine . . . . .	138
6.9	PIXEL Calculations on Olanzapine . . . . .	141
6.10	Concomitant Appearance of Form III with Other Polymorphs of Olanzapine . . . . .	144
6.11	Prolific Solvate Formation of Olanzapine . . . . .	145

6.12	Challenges with Crystal Structure Prediction of Olanzapine and Unobserved Calculated Structures . . . . .	146
6.13	Summary . . . . .	147
	References . . . . .	148
<b>7</b>	<b>Exploring the Physical Form Landscape of Clozapine, Amoxapine and Loxapine.</b> . . . .	<b>153</b>
7.1	Introduction. . . . .	153
7.1.1	Background of Molecule in Group 1-Clozapine . . . . .	154
7.1.2	Background of Molecules in Group 2-Amoxapine and Loxapine. . . . .	154
7.2	Experimental Details . . . . .	155
7.2.1	Principal Component Analysis of Solvent Properties. . . . .	155
7.2.2	Crystallisation Experiments of Clozapine . . . . .	155
7.2.3	Crystallisation Experiments of Amoxapine . . . . .	155
7.2.4	Crystallisation Experiments of Loxapine . . . . .	156
7.2.5	Preliminary Crystal Structure Prediction Studies for Clozapine, Amoxapine and Loxapine. . . . .	158
7.2.6	Solid-State Calculations Using CASTEP . . . . .	158
7.2.7	Structure Analysis . . . . .	159
7.3	Results and Discussion . . . . .	159
7.3.1	Physical Form Screening of Clozapine . . . . .	159
7.3.2	Physical Form Screening Results of Amoxapine. . . . .	173
7.3.3	Physical Form Screening Results of Loxapine . . . . .	178
7.4	Summary . . . . .	190
	References . . . . .	191
<b>8</b>	<b>Conclusions and Further Work</b> . . . . .	<b>195</b>
8.1	Conclusions and Further Work . . . . .	195
8.1.1	Development and Validation of High Throughput Crystallisation and Analysis Methodology for Physical Form Screening . . . . .	198
8.1.2	Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques. . . . .	198
8.1.3	Exploring the Physical Form Landscape of Structurally Related Pharmaceutical Molecules in Group 1 (Olanzapine and Clozapine) and 2 (Amoxapine and Loxapine) . . . . .	199
8.2	Further Work . . . . .	201
8.2.1	Development and Validation of High Throughput Crystallisation and Analysis Methodology for Physical Form Screening . . . . .	201
8.2.2	Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques. . . . .	202

8.2.3	Exploring the Physical Form Landscape of Structurally Related Pharmaceutical Molecules in Group 1 (Olanzapine and Clozapine) and 2 (Amoxapine and Loxapine) . . . . .	203
	References . . . . .	204
<b>Appendix</b>	. . . . .	<b>207</b>

<http://www.springer.com/978-3-319-27554-3>

Control and Prediction of Solid-State of  
Pharmaceuticals

Experimental and Computational Approaches

Bhardwaj, R.M.

2016, XXXVII, 238 p. 121 illus., 77 illus. in color.,

Hardcover

ISBN: 978-3-319-27554-3